Clinical trial · Observational
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry
NCT02392078CI-TRIAL-00088873LAANTERNcompletedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS has been used in over 2600 procedures conducted at over 70 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 5 years to evaluate safety, QoL, and procedural outcomes including local control failure rate, progression free survival, overall survival, and seizure freedom in up to 3,000 patients and up to 50 sites.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epileptic/Seizure Foci | — | UNRESOLVED | — |
| Metastatic Brain Tumor | Brain Neoplasm | CURATED_BROADER | 0.78 |
| Movement Disorders | — | UNRESOLVED | — |
| Primary Brain Tumor | Primary Brain Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NeuroBlate System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Safety (Reportable Adverse Events)
- timeFrame
- up to 5 years or last follow up
- description
- Safety profile described by the NBS and surgical-related AEs
- measure
- Reason for NeuroBlate
- timeFrame
- Index procedure
- description
- To identify the primary reason the NeuroBlate system was chosen for subject
- measure
- Number of Patients Demonstrating Seizure Freedom (ENGEL and ILAE Classifications)
- timeFrame
- up to 5 years or last follow up
- description
- Collected for all subjects by disease etiology. Seizure freedom assessed for all subjects with epilepsy at time of last follow-up. The ENGEL surgical outcome scale is composed of four classes of epilepsy (Class I (best), Class II, Class III, Class IV (worst)) categorized by severity. The ILAE outcome scale contains six classes (Class 1 (best), 2, 3, 4, 5, 6 (worst)) categorized by severity.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Subject or legally authorized representative provides written authorization and/or consent 2. Subject who is to undergo thermal therapy by the NeuroBlate® System for treatment of their neurological disorder Exclusion Criteria: 1. Subject who is, or is expected to be inaccessible for follow-up 2. Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the investigator, may prevent participation or otherwise render subject ineligibility for the study
References
Publications (4)
- DERIVEDLeuthardt EC, Chiang V, Hadjipanayis CG, Landazuri P, Placantonakis DG, Abram SR, Sun DA, Smith KA, Mohammadi AM, Chen CC, Williams BJ, Piccioni DE, Hodges TR, Sloan AE, Lega B, Rodriguez A, Lacroix M, Panov F, Razavi HB, Baumgartner J, Abel TJ, Bandt K, Smyth MD, Rao G, Fecci PE, Laxton AW, Tatter SB, Kim AH, Prabhu SS. Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study. J Clin Oncol. 2026 Aug 17:JCO2502604. doi: 10.1200/JCO-25-02604. Online ahead of print. PMID 42607280
- DERIVEDLandazuri P, Shih J, Leuthardt E, Ben-Haim S, Neimat J, Tovar-Spinoza Z, Chiang V, Spencer D, Sun D, Fecci P, Baumgartner J. A prospective multicenter study of laser ablation for drug resistant epilepsy - One year outcomes. Epilepsy Res. 2020 Nov;167:106473. doi: 10.1016/j.eplepsyres.2020.106473. Epub 2020 Sep 22. PMID 33045664
- DERIVEDKim AH, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, Chiang V, Smith K, Williams BJ, Mohammadi AM, Judy K, Sloan A, Tovar-Spinoza Z, Baumgartner J, Hadjipanayis C, Leuthardt EC. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery. 2020 Sep 1;87(3):E338-E346. doi: 10.1093/neuros/nyaa071. PMID 32315434
- DERIVEDRennert RC, Khan U, Bartek J, Tatter SB, Field M, Toyota B, Fecci PE, Judy K, Mohammadi AM, Landazuri P, Sloan AE, Kim AH, Leuthardt EC, Chen CC. Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization. Neurosurgery. 2020 Apr 1;86(4):538-547. doi: 10.1093/neuros/nyz141. PMID 31076762